| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Articles in PresS, published online ahead of print December 10, 2002
Am J Physiol Endocrinol Metab, 10.1152/ajpendo.00315.2002
Submitted on July 15, 2002
Accepted on November 27, 2002
1 Diabetes Section, NIA, NIH, Baltimore, MD, USA
2 Department of Medicine, University of British Columbia, Vancouver, BC, Canada
3 Geriatric Research Laboratory, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA
* To whom correspondence should be addressed. E-mail: delahi{at}partners.org.
A gut insulinotropic peptide, glucagon-like peptide-1 (GLP-1), when given continuously subcutaneously, has been shown to be an effective agent to treat type 2 diabetes. Due to inactivation by dipeptidyl peptidase IV (DPP 1V), it has a very short half-life (90-120 seconds): hence the need for continuous administration. Exendin-4 is an agonist of the GLP-1 receptor. It is not a substrate for DPP 1V and we previously demonstrated that intravenous administration has potent insulinotropic properties in type 2 diabetic volunteers. We evaluated the efficacy of bolus subcutaneous exendin-4 in insulin-naive type 2 diabetic volunteers. Ten patients age 44 to 72 years with mean fasting glucose levels 11.4 ±0.9 mmol/l were enrolled and daily or twice daily bolus subcutaneous exendin-4 was self-administered for one month. Glycosylated hemoglobin, multiple daily capillary blood glucose, 
-cell sensitivity to glucose, and peripheral tissue sensitivity to insulin, were compared before and after treatment.
The greatest decline in capillary blood glucose was seen before bed with a drop from 15.5 to 9.2 mmol/l (P < 0.0001). Glycosylated hemoglobin improved significantly with treatment from 9.1 to 8.3% (P=0.009). -cell sensitivity to glucose was improved as assessed by C-peptide levels during a hyperglycemic clamp. No significant adverse effects were noted or reported. Our data suggests that even with this short duration of therapy, exendin-4 treatment had a significant effect on glucose homeostasis.
This article has been cited by other articles:
|
|
 |
|
  B. Martin, E. Golden, O. D. Carlson, P. Pistell, J. Zhou, W. Kim, B. P. Frank, S. Thomas, W. A. Chadwick, N. H. Greig, et al. Exendin-4 Improves Glycemic Control, Ameliorates Brain and Pancreatic Pathologies, and Extends Survival in a Mouse Model of Huntington's Disease Diabetes, February 1, 2009; 58(2): 318 - 328. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 V. Ionut, D. Zheng, D. Stefanovski, and R. N. Bergman Exenatide can reduce glucose independent of islet hormones or gastric emptying Am J Physiol Endocrinol Metab, August 1, 2008; 295(2): E269 - E277. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 B. K. Yoo, D. M. Triller, and D. J. Yoo Exenatide: A New Option for the Treatment of Type 2 Diabetes Ann. Pharmacother., October 1, 2006; 40(10): 1777 - 1784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. M. Bray Exenatide Am. J. Health Syst. Pharm., March 1, 2006; 63(5): 411 - 418. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. J. Theodorakis, O. Carlson, S. Michopoulos, M. E. Doyle, M. Juhaszova, K. Petraki, and J. M. Egan Human duodenal enteroendocrine cells: source of both incretin peptides, GLP-1 and GIP Am J Physiol Endocrinol Metab, March 1, 2006; 290(3): E550 - E559. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Dungan and J. B. Buse Glucagon-Like Peptide 1-Based Therapies for Type 2 Diabetes: A Focus on Exenatide Clin. Diabetes, April 1, 2005; 23(2): 56 - 62. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C M. B Edwards GLP-1: target for a new class of antidiabetic agents? J R Soc Med, June 1, 2004; 97(6): 270 - 274. [Full Text] [PDF]
|
|
|
|
|
|
D. A. D'Alessio and T. P. Vahl Glucagon-like peptide 1: evolution of an incretin into a treatment for diabetes Am J Physiol Endocrinol Metab, June 1, 2004; 286(6): E882 - E890. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. E. MacDonald, X. Wang, F. Xia, W. El-kholy, E. D. Targonsky, R. G. Tsushima, and M. B. Wheeler Antagonism of Rat {beta}-Cell Voltage-dependent K+ Currents by Exendin 4 Requires Dual Activation of the cAMP/Protein Kinase A and Phosphatidylinositol 3-Kinase Signaling Pathways J. Biol. Chem., December 26, 2003; 278(52): 52446 - 52453. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Thorkildsen, S. Neve, B. D. Larsen, E. Meier, and J. S. Petersen Glucagon-Like Peptide 1 Receptor Agonist ZP10A Increases Insulin mRNA Expression and Prevents Diabetic Progression in db/db Mice J. Pharmacol. Exp. Ther., November 1, 2003; 307(2): 490 - 496. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
| Visit Other APS Journals Online |
